Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04822948
Other study ID # GUT201801
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 6, 2018
Est. completion date December 15, 2020

Study information

Verified date April 2021
Source Integrative Phenomics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Worldwide, 13% of the population had obesity in 2016 and overweight and obesity are recognized as the fifth leading risk factor for death (roughly 5 million deaths per year). In the United States alone, a recent study predicts that over half of the population will have obesity in 2030. At the global level, overweight and obesity are also estimated to account for 44% of diabetes, 23% of heart disease and between 7% to 41% of cancer cases, in addition to numerous other pathologies, including neurological disorders. While obesity and overweight are classified as a general disease (i.e. a body mass index (BMI) above 25 kg/m2 or 30 kg/m2, respectively), there are large variabilities between classifications of obesity observed. For example, sub-populations of obesity present either a rapid or delayed onset of other chronic diseases, such as diabetes or cardiovascular disease. Many studies show that lifestyle interventions are effective in improving overweight and obesity through weight loss, but with very large inter-individual variability, especially in the long-term. These interventions and the respective observed weight loss are also shown to reduce the risk of other cardiovascular or metabolic diseases, demonstrating the importance of weight loss for future quality of life Interestingly, there is a large variation in weight loss when implementing the same dietary or lifestyle changes, even when many factors are accounted for in clinical studies. Similar variable weight loss or metabolic responses are also observed for other obesity treatments, such as pharmaceutical or surgical interventions. Therefore, in order to prevent and treat overweight and obesity, it is critical to progress in the understanding of individual variations in responses (trajectories) to weight loss programs. While biological, environmental, and behavioral factors indeed drive personal responses, recent advances have allowed more insight into how the human body processes these stimuli, namely through microorganisms inhabiting the gastrointestinal tract. Over the last 10 years, the gut microbiota, the 100 billion bacterial cells inhabiting our intestines, has emerged as a recognized factor contributing to our health. Given its access to the food and medicine consumed by an individual, the gut microbiota can be seen as a "super integrator" highly sensitive to our environmental and lifestyle changes. Accumulating evidence has highlighted that the gut microbiota translates these environmental changes by altering its diversity of bacteria or functions and producing molecules that interact with organs and the brain. As part of a weight loss program conducted within the standard of care in a network of clinical centers across France, the investigators set out to establish a cohort to examine the relative contribution of clinical, nutritional, and lifestyle factors related to individual's weight loss success with an emphasis on evaluating the gut microbiome of individuals. Within this context, the investigators are testing whether an individuals' microbiota profile before the real-life dietary intervention influences weight loss responses and changes in metabolic health parameters to a standardized weight loss diet.


Recruitment information / eligibility

Status Completed
Enrollment 1855
Est. completion date December 15, 2020
Est. primary completion date October 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subject having signed the informed consent - Male or female, 18 to 65 years of age - Body Mass Index (BMI) greater than or equal to 25 kg/m² Exclusion Criteria: - Pregnant woman (positive serum pregnancy test for selection) or breastfeeding, - Infected subject under anti-retroviral treatment - Subject with severe hepatic and / or renal insufficiency (awaiting transplant) - Subject with anemia <10 g / dl - Subject with known gastrointestinal illness - Subject having undergone bariatric surgery - Subject with a weight loss > 10% of body weight during the last 3 months (special diet: low calorie diet (slimming diet), special diet (vegetarians, vegans, nutritional supplements) before treatment), - Subject taking pro or prebiotics before treatment - Subject having taken antibiotics in the 2 months preceding inclusion - Subject participating in another clinical study, - Subject not enrolled in the French national healthcare system - Subject not compliing with the exclusion period from the study in which he/she has previously participated

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France RNPC Marseille

Sponsors (2)

Lead Sponsor Collaborator
Integrative Phenomics RNPC (Rééducation Nutritionnelle et Psycho-Comportementale) Network

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Gut microbiota composition Assessment of gut microbiota taxonomic features (e.g. phyla, genus, species) Baseline and Estimated: 105 days
Primary Bodyweight change Bodyweight change calculated relative to baseline body weight 8 weeks
Secondary Gut microbiota richness and diversity Assessment as gene counts and species Baseline and Estimated: 105 days
Secondary Dietary assessment Assessment via standardized Food Frequency Questionnaire Baseline
Secondary Physical activity Assessment via standardized questionnaire Baseline and Estimated: 105 days and 8 months
Secondary General health and well-being Assessment via standardized questionnaire Baseline and Estimated: 105 days and 8 months
Secondary Eating behavior Assessment via standardized questionnaire Baseline and Estimated: 105 days and 8 months
Secondary Body Mass Index (BMI) Height and bodyweight will be measured to report BMI in (kg/m^2) Baseline and Estimated: 105 days and 8 months
Secondary Bodyweight Body weight (kg) measured bi-weekly Baseline, Estimated: 105 days and 8 months
Secondary Waist circumference Waist circumference (cm) measured bi-weekly Baseline, Estimated: 105 days and 8 months
Secondary Body fat mass Body fat mass assessed by bioelectrical impedance Baseline and Estimated: 105 days
Secondary Muscle mass Muscle mass assessed by bioelectrical impedance Baseline and Estimated: 105 days
Secondary Water weight Water weight assessed by bioelectrical impedance Baseline and Estimated: 105 days
Secondary Blood glucose Fasting blood glucose Baseline and Estimated: 105 days
Secondary Insulin Fasting insulin Baseline and Estimated: 105 days
Secondary HbA1c Fasting HbA1c Baseline and Estimated: 105 days
Secondary Blood lipids Fasting triglycerides, LDL, HDL Baseline and Estimated: 105 days
Secondary Blood pressure Systolic and diastolic blood pressure in mmHg Baseline and Estimated: 105 days
Secondary Liver enzymes Fasting levels of AST, ALT, GGT Baseline and Estimated: 105 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A